What is the share price of Innova Captab Ltd (INNOVACAP) today?
The share price of INNOVACAP as on 6th August 2026 is ₹954.05. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Innova Captab Ltd (INNOVACAP) share?
The past returns of Innova Captab Ltd (INNOVACAP) share are- Past 1 week: -1.90%
- Past 1 month: -1.20%
- Past 3 months: 9.32%
- Past 6 months: 34.82%
- Past 1 year: 2.91%
- Past 3 years: N/A%
- Past 5 years: 76.22%
What are the peers or stocks similar to Innova Captab Ltd (INNOVACAP)?
The peers or stocks similar to Innova Captab Ltd (INNOVACAP) include:What is the dividend yield % of Innova Captab Ltd (INNOVACAP) share?
The current dividend yield of Innova Captab Ltd (INNOVACAP) is 0.21.What is the market cap of Innova Captab Ltd (INNOVACAP) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Innova Captab Ltd (INNOVACAP) is ₹5407.76 Cr as of 6th August 2026.What is the 52 week high and low of Innova Captab Ltd (INNOVACAP) share?
The 52-week high of Innova Captab Ltd (INNOVACAP) is ₹1034.85 and the 52-week low is ₹622.What is the PE and PB ratio of Innova Captab Ltd (INNOVACAP) stock?
The P/E (price-to-earnings) ratio of Innova Captab Ltd (INNOVACAP) is 38.38. The P/B (price-to-book) ratio is 4.96.Which sector does Innova Captab Ltd (INNOVACAP) belong to?
Innova Captab Ltd (INNOVACAP) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Innova Captab Ltd (INNOVACAP) shares?
You can directly buy Innova Captab Ltd (INNOVACAP) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Innova Captab Ltd
INNOVACAP Share Price
NSE₹954.050.76% (+7.15)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
INNOVACAP Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
INNOVACAP Performance & Key Metrics
INNOVACAP Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 38.38 | 4.96 | 0.21% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.38 | 5.86 | 0.51% |
100%
Analysts have suggested that investors can buy this stock
from 2 analysts
Price Upside
Earnings Growth
Rev. Growth
INNOVACAP Company Profile
Innova Captab Ltd is an integrated pharmaceutical company involved in manufacturing and trading drugs, offering services across R&D, manufacturing, and distribution of generic formulations and branded generics.
SUNPHARMA
PE Ratio
40.55
40.55
1Y Return
22.30%
22.30%
Buy Reco %
93.33
93.33
TORNTPHARM
PE Ratio
87.91
87.91
1Y Return
40.63%
40.63%
Buy Reco %
82.14
82.14
CIPLA
PE Ratio
30.38
30.38
1Y Return
0.65%
0.65%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
22.19
22.19
1Y Return
18.79%
18.79%
Buy Reco %
53.57
53.57
LUPIN
PE Ratio
20.47
20.47
1Y Return
28.79%
28.79%
Buy Reco %
54.29
54.29
INNOVACAP Sentiment Analysis
INNOVACAP Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
INNOVACAP Stock Summary · May 2026
Strong top‑line momentum underpinned the call, with consolidated FY'26 revenue of INR 1,630 crore and EBITDA rising to INR 250.3 crore, reflecting broad-based volume‑led growth across CDMO and branded generics. Management struck an upbeat, execution‑focused tone, highlighting customer wins, geographic expansion in branded markets, the strategic benefit of recent regulatory credentials, and R&D investments — including a measured, wave‑2 approach to semaglutide — to move into higher value‑added work. They noted meaningful contrast between robust group growth and near‑term operating unevenness as a recently commissioned Jammu site remains underutilized; management reported Jammu is nearing EBITDA breakeven and should start covering fixed costs imminently, which they expect to unlock operating‑leverage benefits as utilization improves. Management also flagged ongoing capital plans to expand Baddi capacity and to commercialize regulated‑market opportunities from the Sharon acquisition, and explained that accounting choices (capitalizing project costs and prior depreciation/finance impact) will support margin expansion. For FY'27 they reiterated a consolidated target of 20%+ revenue growth driven by sustained volume gains.
INNOVACAP Stock Growth Drivers
INNOVACAP Stock Growth Drivers
10Record FY'26 Financial Performance
The company delivered milestone FY'26 results with consolidated revenue of INR 1,630 crore, up 31%
Broad‑Based Segment Growth: CDMO and Branded Generics
Growth in FY'26 was broad‑based across the CDMO and Branded Generics businesses: CDMO revenue reached
INNOVACAP Stock Challenges
INNOVACAP Stock Challenges
4Rising input-cost and geopolitical API-price risk
Management acknowledged that input prices are increasing due to supply-side disruptions and investors flagged a
Realized gross-margin deterioration driven by adverse product mix
The company reported a year‑on‑year gross margin decline and explicitly attributed the deterioration primarily to
INNOVACAP Forecast
INNOVACAP Forecasts
Price
Revenue
Earnings
INNOVACAP Share Price Forecast
INNOVACAP Share Price Forecast
2026
Current
₹954.05
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹954.05
Baseline
Forecast for Aug 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
INNOVACAP Company Revenue Forecast
INNOVACAP Company Revenue Forecast
2026
Current
₹1.64
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2026
Current
₹1.64
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
INNOVACAP Stock EPS (Earnings Per Share) Forecast
INNOVACAP Stock EPS (Earnings Per Share) Forecast
2026
Current
₹24.62
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹24.62
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
INNOVACAP
INNOVACAP
Income
Balance Sheet
Cash Flow
Quarterly Normal View
INNOVACAP Income Statement
INNOVACAP Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 304.83 | 268.32 | 296.39 | 320.42 | 320.79 | 318.12 | 356.03 | 384.57 | 451.95 | 449.37 | ||||||||||
Operating & Other expenses | 257.89 | 224.56 | 252.09 | 268.47 | 269.90 | 267.06 | 299.44 | 328.52 | 380.90 | 382.71 | ||||||||||
EBITDA | 46.94 | 43.76 | 44.30 | 51.95 | 50.89 | 51.06 | 56.59 | 56.05 | 71.05 | 66.66 | ||||||||||
| Depreciation/Amortization | 4.93 | 3.41 | 4.85 | 4.99 | 5.13 | 9.80 | 11.05 | 11.32 | 11.42 | 11.39 | ||||||||||
| PBIT | 42.01 | 40.35 | 39.45 | 46.96 | 45.76 | 41.26 | 45.54 | 44.73 | 59.63 | 55.27 | ||||||||||
| Interest & Other Items | 6.80 | 0.81 | 0.14 | 0.15 | 0.17 | 1.95 | 2.86 | 5.50 | 3.95 | 4.59 | ||||||||||
| PBT | 35.21 | 39.54 | 39.31 | 46.81 | 45.59 | 39.31 | 42.68 | 39.23 | 55.68 | 50.68 | ||||||||||
| Taxes & Other Items | 10.08 | 10.82 | 9.84 | 11.81 | 11.39 | 9.74 | 11.67 | 9.57 | 13.53 | 12.59 | ||||||||||
| Net Income | 25.13 | 28.72 | 29.47 | 35.00 | 34.20 | 29.57 | 31.01 | 29.66 | 42.15 | 38.09 | ||||||||||
| EPS | 4.39 | 5.02 | 5.15 | 6.12 | 5.97 | 5.17 | 5.42 | 5.18 | 7.37 | 6.65 |
INNOVACAP Company Updates
INNOVACAP Stock Peers
INNOVACAP Past Performance & Peer Comparison
INNOVACAP Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Innova Captab Ltd | 38.38 | 4.96 | 0.21% |
| Sun Pharmaceutical Industries Ltd | 40.55 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.91 | 10.82 | 0.68% |
| Cipla Ltd | 30.38 | 3.41 | 0.89% |
INNOVACAP Stock Price Comparison
Compare INNOVACAP with any stock or ETFCompare INNOVACAP with any stock or ETF
INNOVACAP
INNOVACAP Holdings
INNOVACAP Shareholdings
INNOVACAP Promoter Holdings Trend
INNOVACAP Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
INNOVACAP Institutional Holdings Trend
INNOVACAP Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
INNOVACAP Shareholding Pattern
INNOVACAP Shareholding Pattern
INNOVACAP Shareholding History
INNOVACAP Shareholding History
Foreign Institutions
Mutual Funds Invested in INNOVACAP
Mutual Funds Invested in INNOVACAP
No mutual funds holding trends are available
Top 5 Mutual Funds holding Innova Captab Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 3.2368% | Percentage of the fund’s portfolio invested in the stock 0.62% | Change in the portfolio weight of the stock over the last 3 months 0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 31/85 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 2.9491% | Percentage of the fund’s portfolio invested in the stock 1.14% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 67/95 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1399% | Percentage of the fund’s portfolio invested in the stock 0.46% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 30/72 (-2) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing INNOVACAP stock
smallcases containing INNOVACAP stock
Looks like this stock is not in any smallcase yet.
INNOVACAP Events
INNOVACAP Events
INNOVACAP Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
INNOVACAP Dividend Trend
No dividend trend available
INNOVACAP Upcoming Dividends
INNOVACAP Upcoming Dividends
No upcoming dividends are available
INNOVACAP Past Dividends
INNOVACAP Past Dividends
Cash Dividend
Ex DateEx DateJan 30, 2026
Interim
Interim | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Jan 30, 2026
INNOVACAP Stock News & Opinions
INNOVACAP Stock News & Opinions
Articles & Videos
Corporate
Corporate
Innova Captab AGM scheduledInnova Captab announced that the Annual General Meeting(AGM) of the company will be held on 29 June 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Innova Captab consolidated net profit rises 28.78% in the March 2026 quarterNet profit of Innova Captab rose 28.78% to Rs 38.08 crore in the quarter ended March 2026 as against Rs 29.57 crore during the previous quarter ended March 2025. Sales rose 42.28% to Rs 447.80 crore in the quarter ended March 2026 as against Rs 314.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 9.87% to Rs 140.92 crore in the year ended March 2026 as against Rs 128.26 crore during the previous year ended March 2025. Sales rose 31.06% to Rs 1630.02 crore in the year ended March 2026 as against Rs 1243.68 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales447.80314.74 42 1630.021243.68 31 OPM %14.5415.15 -14.9014.97 - PBDT62.0649.11 26 233.44195.80 19 PBT50.6839.31 29 188.26171.02 10 NP38.0829.57 29 140.92128.26 10 Powered by Capital Market - Live
2 months agoCapital Market - Live
Corporate
Corporate
Innova Captab to announce Quarterly ResultInnova Captab will hold a meeting of the Board of Directors of the Company on 7 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Innova Captab consolidated net profit rises 23.25% in the December 2025 quarterNet profit of Innova Captab rose 23.25% to Rs 42.15 crore in the quarter ended December 2025 as against Rs 34.20 crore during the previous quarter ended December 2024. Sales rose 42.29% to Rs 450.29 crore in the quarter ended December 2025 as against Rs 316.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales450.29316.46 42 OPM %15.4114.71 - PBDT67.1050.72 32 PBT55.6845.59 22 NP42.1534.20 23 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Innova Captab incorporates subsidiary named Metal MartInnova Captab has incorporated a subsidiary company named Metal Mart on 22 January 2026. The company will hold 70% stake in Metal Mart. Powered by Capital Market - Live
6 months agoCapital Market - Live
Spotlight
Spotlight
Innova Captab surges after Q3 PAT climbs 23% YoY to Rs 421 crProfit before tax (PBT) increased 22.14% YoY to Rs 55.67 crore during the quarter. Total expenses increased 44% to Rs 396.27 crore in Q3 FY26, compared with Rs 275.19 crore posted corresponding quarter last year. Cost of material consumed stood at Rs 280.83 crore (up 43.46% YoY), employee benefit expenses was at Rs 43.78 crore (up 55.25% YoY) during the period under review. Meanwhile, the company's board declared dividend of Rs 2 per equity share with a face value of Rs 10 each for FY26. The record date has been fixed as on Friday, 30th January 2026. Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain, including research and development, manufacturing, drug distribution and marketing, and exports. The company has three businesses: CDMO (contract development and manufacturing organization) services and products, domestic branded generics, and international branded generics.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Board of Innova Captab recommends interim dividendInnova Captab announced that the Board of Directors of the Company at its meeting held on 23 January 2026, inter alia, have recommended the interim dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Innova Captab fixes record date for interim dividendInnova Captab has fixed 30 January 2026 as record date for payment of interim dividend for FY 2025-26. Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Innova Captab schedules board meetingInnova Captab will hold a meeting of the Board of Directors of the Company on 23 January 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Earnings
Innova Captab consolidated net profit declines 15.23% in the September 2025 quarterNet profit of Innova Captab declined 15.23% to Rs 29.67 crore in the quarter ended September 2025 as against Rs 35.00 crore during the previous quarter ended September 2024. Sales rose 19.54% to Rs 380.38 crore in the quarter ended September 2025 as against Rs 318.20 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales380.38318.20 20 OPM %13.6315.63 - PBDT50.5651.80 -2 PBT39.2446.81 -16 NP29.6735.00 -15 Powered by Capital Market - Live
8 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 31.78%, vs industry avg of 12.48%
Over the last 5 years, market share increased from 0.15% to 0.32%
Over the last 5 years, net income has grown at a yearly rate of 32.52%, vs industry avg of 10.55%